Medicaid Expansion May Help Prevent Kidney Failure and Improve Access to Kidney-Related Care
Study’s findings underscore the key role Medicaid plays in delivering chronic disease care
Article ID: 614993
Released: 14-Mar-2014 8:00 AM EDT
Source Newsroom: American Society of Nephrology (ASN)
• States with broader Medicaid coverage among low-income nonelderly adults had lower incidences of kidney failure from 2001 through 2008.
• Low-income nonelderly kidney failure patients with Medicaid had better access to care in states with broader Medicaid coverage.
Kidney failure affects more than 350,000 nonelderly Americans at a cost of $10 billion per year.
Newswise — Washington, DC (March 20, 2014) — States with broader Medicaid coverage have lower incidences of kidney failure and smaller insurance-related gaps in access to kidney disease care. Those are the findings of a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). The results point to the potential benefits of Medicaid expansion on chronic disease prevention and care.
Chronic disease care is a major source of rising health care expenditures, and access to care for uninsured individuals with a chronic disease has eroded over the last decade. The Affordable Care Act is expanding Medicaid coverage of low-income adults, though not all states are participating in this expansion. Most previous studies of Medicaid coverage have focused on primary care or emergency room services and have not carefully examined Medicaid’s effects on chronic disease care.
The care of patients approaching kidney failure, or end-stage renal disease (ESRD), is a useful model to study the potential effects of Medicaid expansion on chronic disease care because ESRD care is costly and the quality of pre-ESRD care is tracked nationally.
Manjula Tamura, MD, MPH (VA Palo Alto Health Care System and Stanford University) and her colleagues sought to determine whether states with broader Medicaid coverage of low-income non-elderly adults had a lower incidence of ESRD and better access to pre-ESRD care. They also looked to see whether broad state Medicaid coverage benefitted uninsured adults in addition to those receiving Medicaid.
Using US data, the researchers identified 408,535 adults aged 20 to 64 years who developed ESRD from 2001 through 2008. Medicaid coverage among low-income nonelderly adults living in different states ranged from 12.2% to 66.0%.
Among the major findings:
• Broader Medicaid coverage among low-income nonelderly adults was associated with a lower incidence of ESRD: for each additional 10% of the low-income nonelderly population covered by Medicaid, there was a 1.8% decrease in ESRD incidence.
• Low-income nonelderly adults with ESRD who were on Medicaid had better access to care in states with broader Medicaid coverage: For a 50-year-old white woman, the access gap to being put on the kidney transplant waiting list between Medicaid and private insurance decreased by 7.7 percentage points in high vs low Medicaid coverage states. Similarly, the access gap to transplantation decreased by 4.0 percentage points and the access gap to peritoneal dialysis decreased by 3.8 percentage points.
• Broader Medicaid coverage was associated with some spillover benefits for uninsured adults with ESRD, but these were small and not consistently observed.
“Our study suggests that Medicaid expansion among low-income nonelderly adults could support efforts to prevent kidney failure and improve access to kidney disease care,” said Dr. Tamura.
In an accompanying editorial, Rajnish Mehrotra, MD and Larry Kessler, ScD (University of Washington, Seattle) noted that the researchers’ work “highlights the intricate web of health insurance, access to care, and ESRD. Their study is timely as a social experiment is unfolding in this country that will allow us to further examine the association between Medicaid coverage and health care outcomes.”
Study co-authors include Benjamin Goldstein, PhD, MPH, Yoshio Hall, MD, MS, Aya Mitani, MPH, and Wolfgang Winkelmayer, MD, MPH, ScD.
Disclosures: Dr. Tamura has served as a scientific advisor to Amgen and has received honoraria from Satellite Healthcare. Dr. Hall has received research funding from Satellite Healthcare. Dr. Winkelmayer has served as a scientific advisor to or on data safety monitoring boards for Amgen, Bayer, GlaxoSmithKline, Keryx, Medgenics, and Medtronic.
The article, entitled “State Medicaid Coverage, ESRD Incidence, and Access to Care,” will appear online at http://jasn.asnjournals.org/ on March 20, 2014.
The editorial, entitled “Health Insurance, Access to Care, and ESRD: An Intricate Web,” will appear online at http://jasn.asnjournals.org/ on March 20, 2014.
The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.
Founded in 1966, and with more than 14,000 members, the American Society of Nephrology (ASN) leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients.
# # #